Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.

A sale could value Bausch + Lomb at more than $13 billion, according to Bloomberg Intelligence analyst Mike Holland. The news is “certainly welcome to investors tied up in the Gordian’s knot at Bausch ...

Bausch + Lomb is assessing interest from potential buyers as a way around the roadblock, the FT wrote. The company had a market cap of $6.27 billion on Monday.

Bausch + Lomb has a pretty solid balance sheet that hasn’t changed a lot in the last few quarters. Read why I remain bullish ...

Bausch & Lomb (NYSE:BLCO) may be worth around $28 a share in a potential takeover after reports that the eye care company is ...

Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a ...

Researchers at multiple AViDD centers confirm that the NIH has offered a 1-year, no-cost extension, but it doesn’t come with ...

Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation from ...

Bloomberg News Now is a comprehensive audio report on today's top stories. Listen for the latest news, whenever you want it, covering global business stories around the world.

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...